logo
Family Seeks $15 Million in Death of Migrant Girl in U.S. Custody

Family Seeks $15 Million in Death of Migrant Girl in U.S. Custody

New York Times01-05-2025

The death of an 8-year-old migrant girl in 2023 while she was in the custody of U.S. Customs and Border Protection prompted investigations and the removal of the agency's chief medical officer. Now, two immigrant rights groups are seeking $15 million in damages on behalf of the girl's family.
In a wrongful death claim filed with the federal government on Thursday, lawyers for the family offer the most detailed public account yet of the life and death of the child, Anadith Danay Reyes Álvarez, and her family's efforts to obtain answers about her care in federal custody.
Her death came during a record increase in migration, as the Biden administration struggled to curb illegal crossings and faced criticism about overcrowded detention facilities and the treatment of minors. Illegal crossings plunged in the final months of the Biden administration after a change in asylum policy, and have remained very low under President Trump. But the Trump administration has made families with children targets for detention and removal as President Trump seeks to fulfill a campaign pledge to deport millions of undocumented immigrants.
Rochelle Garza, president of the Texas Civil Rights Project, one of the groups that filed the claim, said Anadith's family wanted to ensure there was accountability and transparency in Customs and Border Protection facilities, which she described as 'one of the most obscure and opaque types of detention in our American immigration system.'
'They do not want their daughter to have died in vain,' Ms. Garza said.
Customs and Border Protection, Immigration and Customs Enforcement and the Department of Homeland Security did not respond to requests for comment on the wrongful death claim. After Anadith's death, Troy Miller, then acting head of the border agency, requested a review of CBP facilities and made recommendations to address the medical care issues.
Anadith, a Panamanian national, was diagnosed with sickle cell disease and a heart condition at a young age. When she was 5, she traveled with her father to Spain for open-heart surgery and returned to Panama. The family made their way up through Mexico and sought to cross into the United States in May 2023 in hopes of providing safety and a better life for their daughter, according to the complaint.
Her parents, who are Honduran, are members of a long-persecuted Afro-Indigenous population known as Garifuna, and had fled their own country before their daughter was born. The other immigrant rights group that filed the family's legal claim was the Haitian Bridge Alliance, which focuses on serving Black immigrants.
On May 9, 2023, she, her parents and two siblings were detained alongside other migrants at the border near Brownsville, Texas. The family was then taken to a processing center in Donna, a nearby city, where security camera footage showed her parents handed over their daughter's medical records to border officials in a medical screening area, the claim states. But medical personnel there did not properly assess her medical history or communicate the details of her medical conditions to the staff at the facility in Harlingen where the family ended up, investigators have found.
Anadith and her family were held in custody for nine days, more than twice as long as newly arrived migrants, particularly children, should be detained, according to the border agency's own standards. In that time, Anadith exhibited a high fever and complained of pain in her chest and abdomen, among other symptoms, lawyers said.
The claim contends immigration officials failed to provide the girl with proper medical care and to adhere to a 22-year-old consent decree that lays out the minimum standards for care of the nation's youngest new arrivals. Between the evening of May 14 and her death on May 17, an internal investigation found, medical professionals at the holding facility in Harlingen saw Anadith at least nine times. A nurse practitioner who saw the child told internal investigators that she dismissed three or four requests from Anadith's mother to call an ambulance or take the child to the hospital.
The previous year, a report from the detention ombudsman at Homeland Security had warned that critical shortages in medical services at border facilities could put migrants' lives at risk. A report from the Senate Judiciary Committee earlier this year found the circumstances of Anadith's death were 'not an aberration, but indicative of systemic problems' within border facilities and medical care.
Anadith's family is now in the process of seeking asylum, and her parents have secured work permits, lawyers said.
In an interview on Thursday, the girl's mother, Mabel Álvarez, said her family had filed the claim in hopes of preserving Anadith's memory and preventing another tragedy. She recalled that her daughter was healthy when she first arrived at the South Texas border. But she said the small room where her family was detained was filthy with trash and dust. She also recalled it was frigid, the reason such facilities are often referred to as 'hieleras,' or coolers.
Ms. Álvarez wept as she described staff members who she said ignored her pleas for medical attention as her daughter's condition worsened. After the family's release from immigration detention, Ms. Álvarez said, she took on a job at a factory in New York, but she had to leave it as she struggled with depression and anxiety.
'It was a difficult thing, that my daughter died in my arms, looking for help,' she said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

USA Today

time2 hours ago

  • USA Today

Texas politicians lead effort to study a psychedelic drug. What is ibogaine?

Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.

This New Test Could Diagnose Parkinson's With AI
This New Test Could Diagnose Parkinson's With AI

Newsweek

time3 hours ago

  • Newsweek

This New Test Could Diagnose Parkinson's With AI

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A new artificial intelligence (AI) tool analyzing short smile videos achieved high accuracy in screening for Parkinson's disease (PD), according to research published by Tariq Adnan, and colleagues in the New England Journal of Medicine (NEJM) Thursday. The model was trained on the largest known video dataset of facial expressions to date, enrolling 1,452 participants, including 391 living with PD. An 87.9 percent overall accuracy in detecting PD using only smile video analysis, the NEJM AI study reported. Researchers reported that the AI model could accurately distinguish between individuals with and without PD based on the analysis of their smiles, even when applied in diverse population samples from North America and Bangladesh. Why It Matters The Parkinson's Foundation says an estimated 90,000 more people will be diagnosed this year, with the number of those suffering expected to be around 1.2 million by 2030. Diagnosing Parkinson's disease early remains a significant challenge because of limited access to clinical expertise and in-person evaluations. AI-driven remote screening tools promise scalable, cost-effective solutions to bridge these healthcare gaps. The findings align with the growing demand for digital healthcare solutions that remove geographical and economic barriers to early neurological disease diagnosis, which is especially relevant to rural and underserved American communities. What To Know The new screening method invited participants to record themselves mimicking facial expressions—including a smile—using an online platform. Research teams then extracted facial landmarks and measured action units to quantify hypomimia, a common motor symptom in PD where facial muscle movement is diminished. Machine learning models were developed using these features, distinguishing people with PD from those without. The approach relied on a broad recruitment strategy, involving participants from North America via social media, email, wellness centers, and research registries, alongside a high-risk cohort from Bangladesh. Trained solely on smile videos, the model achieved a 10-fold cross-validated accuracy of 87.9 percent, a sensitivity of 76.8 percent, and a specificity of 91.4 percent. Validation in external test sets revealed 80.3 percent accuracy in a U.S. clinic dataset and 85.3 percent accuracy in the Bangladesh cohort. While the negative predictive value remained above 92 percent in all settings, the positive predictive value dropped to 35.7 percent among the Bangladeshi participants, reflecting variations in population characteristics. The study found no significant differences in model performance across sex and ethnic subgroups, except for marginally higher accuracy in female participants in Bangladesh. The authors emphasized the generalizability and fairness of the approach, key considerations in the development of clinical AI tools. The video-processing and machine-learning code supporting the study is available to the public on GitHub. However, the study authors noted that raw video data sharing is restricted to comply with U.S. healthcare privacy law (HIPAA), limiting access to de-identified derivative features only. The research received funding from the National Institute of Neurological Disorders and Stroke at the National Institutes of Health, among other sources. The work was a collaborative effort involving academic and clinical partners such as the InMotion Parkinson's Disease wellness center and the University of Rochester Center for Health and Technology. The research process also benefited from contributions by staff at Google Research and the University of Rochester, particularly in statistical analysis. Stock image of brain MRI taken November 21, 2018. Stock image of brain MRI taken November 21, 2018. Getty What People Are Saying Tariq Adnan, lead author said in the study conclusion: "Smiling videos can effectively differentiate between individuals with and without PD, offering a potentially easy, accessible, and cost-efficient way to screen for PD, especially when access to clinical diagnosis is limited." What Happens Next? Future steps for the research team involve wider validation of the AI screening method in additional, real-world populations and further refinement of the algorithm to maximize early detection accuracy. Regulatory and clinical translation pathways will determine if and when this technology becomes available in the United States healthcare system.

Doctor Discusses Fishy Surgery That Saved Bald Eagle's Life
Doctor Discusses Fishy Surgery That Saved Bald Eagle's Life

Newsweek

time4 hours ago

  • Newsweek

Doctor Discusses Fishy Surgery That Saved Bald Eagle's Life

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Thanks to an innovative surgery using fish skin grafts, Kere, a rescued bald eagle, returned to flight over Wisconsin on June 22 after surviving a life-threatening leg injury. Why It Matters Bald eagles, the national symbol of the United States, have faced near extinction in the past, with each rescue effort highlighting conservation progress and ongoing challenges. In Kere's case, the pioneering use of fish skin grafts to heal traumatic wounds in wildlife opens a potential new chapter in animal medical care. The bald eagle's release came days ahead of July Fourth celebrations, restoring an emblem of American freedom to the wild. What To Know Kere's 10-month recovery was led by Dr. Kim Ammann, a raptor specialist and founder at the Winged Freedom Raptor Hospital, a press release provided to Newsweek said. The treatment represented the first time a bald eagle received this type of skin graft that was provided by Icelandic firm Kerecis. Kere was discovered in Hayward, Wisconsin, in September 2024 with a 360-degree wound running from her knee to her ankle. The injury left no healthy skin for traditional treatments and infection threatened her survival. Ammann then stepped in to provide care. "With no traditional options left, she turned to innovative alternatives and discovered an Icelandic company called Kerecis that uses intact fish skin from sustainably sourced North Atlantic Cod to support tissue regeneration," the press release said. Kerecis, known for developing fish skin grafts for humans, had only recently begun offering veterinary products. Over 10 months, the cod skin grafts supported tissue regeneration and helped combat infection, which improved Kere's prospects. "The trust she put in me made it possible to accomplish what we did. She tolerated bandage changes every few days for months," Ammann said. Ammann, who treated over 200 birds in the past year, including 75 bald eagles, noted that Kere's case demonstrates the importance of innovative veterinary efforts. The successful use of fish skin grafts may open doors for wildlife rescue centers and veterinarians nationwide. Stock photo. A bald eagle flies over the Massapequa Preserve on March 25 in Massapequa, New York. Stock photo. A bald eagle flies over the Massapequa Preserve on March 25 in Massapequa, New York. Photo byWhat People Are Saying Dr. Kim Ammann, founder of Winged Freedom Raptor Hospital, said about Kere: "She left the wraps and dressings alone as they were healing her wound. She was eating well and taking necessary medications the whole time." Marta Hines, veterinary business development manager at Kerecis, said in the press release: "Our fish skin grafts are used in a variety of different wounds, whether those are traumatic wounds or some that have been out there for a while, and they have not closed in a while, like chronic wounds." What Happens Next The Winged Freedom Raptor Hospital continues to seek support for its conservation and rehabilitation activities. Kerecis, meanwhile, has indicated continued research and development of its veterinary products.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store